STOKE THERAPEUTICS INC (STOK) Stock News
NASDAQ:STOK - Nasdaq - US86150R1077 - Common Stock - Currency: USD
STOK Latest News, Press Relases and Analysis
STOKE THERAPEUTICS INC (NASDAQ:STOK) – A Biotech Stock with Strong Growth Signals
STOKE THERAPEUTICS (NASDAQ:STOK) shows strong growth metrics, high profitability improvements, and attractive valuation, making it a candidate for growth investors following Louis Navellier's strategy.
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet
The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 613.51% and 1,391.01%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BRTX
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Doximity Q4 Earnings Likely to Reflect Strong Product Momentum
Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.
BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut
Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year.
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: CGON
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar
The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs.
Mentions: BIIB
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: BPMC
Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?
Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Stoke Therapeutics Announces CEO Transition
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug
Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the latest effort by the biotech company to fill holes in its pipeline.
Mentions: BIIB
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
